Royalty Pharma plc Remaining Share Repurchase Authorization
Royalty Pharma plc (RPRX) had Remaining Share Repurchase Authorization of $1.70 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Equity
us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 · last filed 2026-08-05
- 2026-06-30: Stock Repurchase Program, Remaining Authorized Repurchase Amount $1.70B.
- 2026-03-31: Stock Repurchase Program, Remaining Authorized Repurchase Amount $1.70B.
- 2025-12-31: Stock Repurchase Program, Remaining Authorized Repurchase Amount $1.80B.
- 2025-09-30: Stock Repurchase Program, Remaining Authorized Repurchase Amount $1.90B.
| Period end | Stock Repurchase Program, Remaining Authorized Repurchase Amount |
|---|---|
| 2026-06-30 | $1.70B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $1.70B 10-Q · filed 2026-05-06 |
| 2025-12-31 | $1.80B 10-K · filed 2026-02-11 |
| 2025-09-30 | $1.90B 10-Q · filed 2025-11-05 |
| 2025-06-30 | $2.00B 10-Q · filed 2025-08-06 |
| 2025-03-31 | $2.30B 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |